Cytotoxicity studies of combination of proteasome inhibitor Velcade and hyperthermia

10^th Global Annual Oncologists Meeting

July 11-13, 2016 Cologne, Germany

Timur Saliev, Loreto B Feril Jr, Dinara Begimbetova, Dinara Baiskhanova, Xenia Bobrova, Mars Akishev and Katsuro Tachibana

Nazarbayev University, Kazakhstan
Fukuoka University School of Medicine, Japan

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

One of perspective methods of cancer treatment is the induction of apoptosis (â��programmed cell deathâ��) in malignant cells. The apoptosis can be stimulated by various factors: biological, chemical and physical. We investigated cytotoxic effect of combination of pharmacological apoptosis modulator Velcade (Janssen-Cilag Pty Ltd) and hypethermia. The cytotoxicity was studied for 5 concentrations of Velcade (1, 2, 3, 4 and 5 ng/ml), three types of temperature (40, 42 and 44�°C), and two types of cancer cells (human melanoma C-32 and human monocytic leukaemia U937 lines). The results demonstrated that Velcade in all 5 concentrations was able of suppress the viability of U937 cells. The decrease in cell survival rate was in a direct correlation with the increase of drugâ��s concentration. The maximal level of dead cells was detected for 40�°C for all concentrations of Velcade. However, the acquired data showed that the augmentation of temperature up to 42�°C and 44�°C resulted in the rise of number of viable cells. These findings indicate that high temperatures have a cyto-protective effect. The possible mechanism may lay in the ability of mild hyperthermia to promote cell growth. The second feasible explanation is a negative impact of high temperature on Velcadeâ��s pharmacodynamics. The data of cytotoxicity studies of C-32 cells showed a similar picture. The elevation of temperature led to the decrease of cells viability. Notably, the highest temperature (44�°C) had a cyto-protective effect too. In conclusion, our findings indicate that combination of apoptosis modulator Velcade and mild hypethermia can be effectively employed for the elimination of cancer cells.

Biography :

Timur Saliev, is a Lead Scientist and obtained his PhD (Bio-physics) at the University of Dundee (United Kingdom), Medical degree (MD) from Tashkent Pediatric Medical Institute (Uzbekistan) with specialization in Anesthesiology & Intensive care; M.Sci. (Bio-physics) obtained from Wageningen University (Netherlands). His areas of research interest inclyde bio-physics, therapeutic applications of ultrasound and other non-invasive physical modalities, nano-technology, cancer treatment, imaging, drug & gene delivery systems, advanced microscopy, medical robotics, pharmacology and development of medical devices and instruments. Currently, he is supervising projects related to bio-physics at the Center for Life Sciences (NLA, NU).

Email: tim.saliev@gmail.com